Neel Mehta
Agilent Technologies is working with the newly-established Duke Molecular Physiology Institute to help carry out translational research in chronic disease by using Agilent’s biology tools.
The DMPI research team received a grant from Agilent to use the company’s tools as the institute aims to learn more about cardiovascular and other cartometabolic diseases, the company announced Monday.
DMPI will be led by Christopher Newgard, Duke University School of Medicine’s Department of Pharmacology and Cancer Biology professor and Sarah W. Stedman Nutrition and Metabolism Center and the Institute for Molecular Physiology director.
“The Duke Molecular Physiology Institute seeks to combine strong genomics, epigenomics, transcriptomics and metabolomics platforms with computational biology, clinical translation and basic science expertise to gain new insights into the mechanisms of cardiometabolic diseases,” Newgard said.
